文摘
摘要目的:偏头痛患者描述驾驶行为的观察性流行病学的调查中,偏头痛(克服)研究的治疗和护理。
背景:偏头痛与实质功能的负担,但对migraine-related驾驶障碍。
设计/方法:克服代表我们是一个基于网络的调查样本。样品收集在2019年春季偏头痛在驱动频率的影响,评估期间驾驶期间避免头痛,和天无法开车。每月头痛的日子(磁流体动力),大富翁得分,头痛,attack-related残疾评估。分类变量之间的差异进行评估与卡方统计和相关性进行评估与斯皮尔曼的ρ(r)。
结果:5485名合格参与者与偏头痛和有效的驾驶执照,意味着(SD)年龄为49.7岁(14.2)和磁流体动力是5.9 (7.0);13.2%有慢性偏头痛。MIDAS得分是14.3 (26.1);19.5%有严重MIDAS残疾。随着疼痛强度的增加,报告与头痛不开车从轻度增加比例(27.1%),中度(38.4%),重度疼痛(66.0%)(p < 0.0001) vs温和。开车时间避免MIDAS等级的增加而增加(r = 0.39), attack-related残疾(r = 0.39),和磁流体动力(r = 0.18;p < 0.0001)。患者的比例≥7小时开车避免增加与中度(26.6%),重度残疾(37.1%)非常严重(52.1%)(p < 0.001)。患者的工作能力严重受损或需要卧床休息,25.4%和42.9%报道≥7小时的驾驶期间避免攻击。天无法开车过去90天增加migraine-related残疾和磁流体动力增加(p < 0.001)。
结论:越来越多的偏头痛患者避免驾驶随着疼痛强度增加,达到66%的严重疼痛。开车避免持续≥7小时发生在几乎一半的那些有严重的残疾。偏头痛对驾驶的影响价值额外的关注和临床评估。
披露:立顿博士已经收到个人赔偿咨询、担任科学顾问委员会说,与梯瓦制药或其他活动。立顿博士已经收到补偿服务的董事会eNeura Biohaven。立顿博士持有股票或股票期权的Biohaven立顿博士是参与赞助的研究作为一个侦探。立顿博士在Biohaven持有股票或股票期权。立顿博士收到偏头痛研究基金会的研究支持国家头痛基金会和Amgen.Dr。厕所已收到个人赔偿咨询、担任科学顾问委员会说,或其他活动与礼来公司员工和Company.Dr。Araujo已收到个人赔偿咨询、担任科学顾问委员会说,与礼来公司和公司员工或其他活动。Nicholson博士已经收到个人赔偿咨询、担任科学顾问委员会说,与礼来公司和公司员工或其他活动。Nicholson博士已经收到赔偿在礼来公司和公司的董事会。Nicholson博士持有股票或股票期权在礼来公司赞助的研究Nicholson博士是作为一个侦探。 Dr. Nicholson holds stock and/or stock options in Eli Lilly and Company. Dr. Nicholson has received research support from Eli Lilly and Company. Dr. Zagar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Kim has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Doty has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Doty holds stock and/or stock options in Eli Lilly. Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Li holds stock and/or stock options in Eli Lilly and Company. Dr. Buse has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dawn C. Buse, PhD, has received grant support and honoraria from Allergan, Avanir, Amgen, Biohaven, Eli Lilly and Company, and Promius and for work on the editorial board of Current Pain and Headache Reports.. Dr. Buse has received personal compensation in an editorial capacity for Dawn C. Buse, PhD, has received grant support and honoraria from Allergan, Avanir, Amgen, Biohaven, Eli Lilly and Company, and Promius and for work on the editorial board of Current Pain and Headache Reports.. Dr. Buse has received research support from Dawn C. Buse, PhD, has received grant support and honoraria from Allergan, Avanir, Amgen, Biohaven, Eli Lilly and Company, and Promius and for work on the editorial board of Current Pain and Headache Reports.. Dr. Shapiro has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company for consulting on research studies. Dr. Reed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with OVERCOME study advisory board. Dr. Reed has received research support from Michael L. Reed, PhD, is Managing Director of Vedanta Research, which has received research funding from Allergan, Amgen, Promius/Dr. Reddy’s Laboratories, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novartis the National Headache Foundatio.Dr. Pearlman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Pearlman holds stock and/or stock options in Eli Lilly and Company.
